JAK inhibitor 'sound option' for patients with severe COVID-19
The agent is as effective as dexamethasone for hospitalised patients, in combination with an antiviral, but has fewer adverse events
The Janus kinase inhibitor baricitinib is just as effective as dexamethasone for patients hospitalised with COVID-19 and has a superior safety profile, a landmark study shows.
The results from the first head-to-head trial of its kind could help doctors decide which immunomodulator to use, based on patient risk of dexamethasone-related side effects, international researchers say.
“For the bedside clinician, a more individually tailored choice of immunomodulation now appears possible,
